News

The small and medium sized enterprise (SME) program is a new initiative by the EMEA (European Agency for the Evaluation of Medicinal Products) dedicated to addressing the particular

Group operating income rose to 31%, driven by pharmaceuticals and Sandoz as well as one-time divestment gain in consumer health. Net income climbed 32% to $2 billion, or

The initial US-based phase Ib trial will evaluate NOV-205 as monotherapy for chronic hepatitis C genotype 1 patients who have failed pegylated interferon plus ribavirin therapy – the

BioSante’s objective in the preclinical study was to determine whether BioVant could enhance the body’s natural immune response to the H5N1 viral antigen, the cause of bird flu.

In the The Journal of Clinical Investigation, researchers from the National Human Genome Research Institute, the National Eye Institute, and the National Institute of Child Health and Human

In a study published in the journal Blood, Dr Ofer Levy and colleagues show that the newborn immune system functions differently than that of adults, but that one

During its next fiscal year Medtronic will invest in at least six new major clinical trials of therapies that use its neuromodulation or radio-frequency technology to treat a

Under the terms of the agreement, Cytogen sold its 50% interest in PSMA Development Company (PDC) to Progenics for an upfront cash payment of $13.2 million, potential future

Safetek is currently conducting further due diligence on Resdevco, based in Jerusalem, Isreal, and its intellectual property, but the company intends that a definitive agreement will be executed